HuGE Literature Finder
Records
1
-
5
Biochip-based approach for comprehensive pharmacogenetic testing. Drug metabolism and personalized therapy 2020 Dec . Ikonnikova Anna Yu, Filippova Marina A, Surzhikov Sergey A, Pozhitnova Victoria O, Kazakov Ruslan E, Lisitsa Tatiana S, Belkov Sergey A, Nasedkina Tatiana |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British journal of cancer 2017 Aug . Lévi Francis, Karaboué Abdoulaye, Saffroy Raphaël, Desterke Christophe, Boige Valerie, Smith Denis, Hebbar Mohamed, Innominato Pasquale, Taieb Julien, Carvalho Carlos, Guimbaud Rosine, Focan Christian, Bouchahda Mohamed, Adam René, Ducreux Michel, Milano Gérard, Lemoine Antoinet |
Ecto-5' -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients - Data from the German Calciphylaxis Registry. PloS one 2017 12 (2): e0172407. Rothe Hansjörg, Brandenburg Vincent, Haun Margot, Kollerits Barbara, Kronenberg Florian, Ketteler Markus, Wanner Christo |
[Personalized drug therapy-directed clinical pharmacology research based on genetic polymorphisms and pharmacokinetics analysis]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 2013 133 (10): 1079-85. Hayashi Hide |
Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 Jan 18 (1): 49-56. Nimptsch Katharina, Rohrmann Sabine, Nieters Alexandra, Linseisen Jak |
- Page last reviewed:Oct 1, 2021
- Page last updated:May 20, 2022
- Content source: